L. Davies, L.G. Morris, M. Haymart, A.Y. Chen, D. Goldenberg, J. Morris, J.B. Ogilvie, D.J. Terris, J. Netterville, R.J. Wong, G. Randolph; AACE Endocrine Surgery Scientific Committee, American Association of Clinical Endocrinologists and American College of endocrinology disease state clinical review: the increasing incidence of thyroid cancer. Endocr. Pract. 21(6), 686–696 (2015). https://doi.org/10.4158/EP14466.DSCR

Article  PubMed  PubMed Central  Google Scholar 

M. Schlumberger, M. Brose, R. Elisei, S. Leboulleux, M. Luster, F. Pitoia, F. Pacini, Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol. 2(5), 356–358 (2014). https://doi.org/10.1016/S2213-8587(13)70215-8

Article  PubMed  Google Scholar 

M.S. Brose, C.M. Nutting, B. Jarzab, R. Elisei, S. Siena, L. Bastholt, C. de la Fouchardiere, F. Pacini, R. Paschke, Y.K. Shong, S.I. Sherman, J.W. Smit, J. Chung, C. Kappeler, C. Peña, I. Molnár, M.J. Schlumberger; DECISION investigators, Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomized, double-blind, phase 3 trial. Lancet 384(9940), 319–328 (2014). https://doi.org/10.1016/S0140-6736(14)60421-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

M. Schlumberger, M. Tahara, L.J. Wirth, B. Robinson, M.S. Brose, R. Elisei, M.A. Habra, K. Newbold, M.H. Shah, A.O. Hoff, A.G. Gianoukakis, N. Kiyota, M.H. Taylor, S.B. Kim, M.K. Krzyzanowska, C.E. Dutcus, B. de las Heras, J. Zhu, S.I. Sherman, Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med. 372(7), 621–630 (2015). https://doi.org/10.1056/NEJMoa1406470

Article  CAS  PubMed  Google Scholar 

M.S. Brose, B. Robinson, S.I. Sherman, J. Krajewska, C.C. Lin, F. Vaisman, A.O. Hoff, E. Hitre, D.W. Bowles, J. Hernando, L. Faoro, K. Banerjee, J.W. Oliver, B. Keam, J. Capdevila, Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 22(8), 1126–1138 (2021). https://doi.org/10.1016/S1470-2045(21)00332-6

Article  CAS  PubMed  Google Scholar 

D.S. Hong, S.G. DuBois, S. Kummar, A.F. Farago, C.M. Albert, K.S. Rohrberg, C.M. van Tilburg, R. Nagasubramanian, J.D. Berlin, N. Federman, L. Mascarenhas, B. Geoerger, A. Dowlati, A.S. Pappo, S. Bielack, F. Doz, R. McDermott, J.D. Patel, R.J. Schilder, M. Tahara, S.M. Pfister, O. Witt, M. Ladanyi, E.R. Rudzinski, S. Nanda, B.H. Childs, T.W. Laetsch, D.M. Hyman, A. Drilon, Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 21(4), 531–540 (2020). https://doi.org/10.1016/S1470-2045(19)30856-3

Article  CAS  PubMed  PubMed Central  Google Scholar 

S.G. Waguespack, A. Drilon, J.J. Lin, M.S. Brose, R. McDermott, M. Almubarak, J. Bauman, M. Casanova, A. Krishnamurthy, S. Kummar, S. Leyvraz, D.Y. Oh, K. Park, D. Sohal, E. Sherman, R. Norenberg, J.D. Silvertown, N. Brega, D.S. Hong, M.E. Cabanillas, Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Eur. J. Endocrinol. 186(6), 631–643 (2022). https://doi.org/10.1530/EJE-21-1259

Article  CAS  PubMed  PubMed Central  Google Scholar 

R.C. Doebele, A. Drilon, L. Paz-Ares, S. Siena, A.T. Shaw, A.F. Farago, C.M. Blakely, T. Seto, B.C. Cho, D. Tosi, B. Besse, S.P. Chawla, L. Bazhenova, J.C. Krauss, Y.K. Chae, M. Barve, I. Garrido-Laguna, S.V. Liu, P. Conkling, T. John, M. Fakih, D. Sigal, H.H. Loong, G.L. Buchschacher Jr, P. Garrido, J. Nieva, C. Steuer, T.R. Overbeck, D.W. Bowles, E. Fox, T. Riehl, E. Chow-Maneval, B. Simmons, N. Cui, A. Johnson, S. Eng, T.R. Wilson, G.D. Demetri; trial investigators, Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 21(2), 271–282 (2020). https://doi.org/10.1016/S1470-2045(19)30691-6

Article  CAS  PubMed  Google Scholar 

L.J. Wirth, E. Sherman, B. Robinson, B. Solomon, H. Kang, J. Lorch, F. Worden, M. Brose, J. Patel, S. Leboulleux, Y. Godbert, F. Barlesi, J.C. Morris, T.K. Owonikoko, D.S.W. Tan, O. Gautschi, J. Weiss, C. de la Fouchardière, M.E. Burkard, J. Laskin, M.H. Taylor, M. Kroiss, J. Medioni, J.W. Goldman, T.M. Bauer, B. Levy, V.W. Zhu, N. Lakhani, V. Moreno, K. Ebata, M. Nguyen, D. Heirich, E.Y. Zhu, X. Huang, L. Yang, J. Kherani, S.M. Rothenberg, A. Drilon, V. Subbiah, M.H. Shah, M.E. Cabanillas, Efficacy of selpercatinib in RET-altered thyroid cancers. N. Engl. J. Med. 383(9), 825–835 (2020). https://doi.org/10.1056/NEJMoa2005651

Article  CAS  PubMed  PubMed Central  Google Scholar 

V. Subbiah, M.I. Hu, L.J. Wirth, M. Schuler, A.S. Mansfield, G. Curigliano, M.S. Brose, V.W. Zhu, S. Leboulleux, D.W. Bowles, C.S. Baik, D. Adkins, B. Keam, I. Matos, E. Garralda, J.F. Gainor, G. Lopes, C.C. Lin, Y. Godbert, D. Sarker, S.G. Miller, C. Clifford, H. Zhang, C.D. Turner, M.H. Taylor, Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol. 9(8), 491–501 (2021). https://doi.org/10.1016/S2213-8587(21)00120-0

Article  CAS  PubMed  Google Scholar 

N.L. Busaidy, B. Konda, L. Wei, L.J. Wirth, C. Devine, G.A. Daniels, J.A. DeSouza, M. Poi, N.D. Seligson, M.E. Cabanillas, J.A. Sipos, M.D. Ringel, A.K. Eisfeld, C. Timmers, M.H. Shah, Dabrafenib versus Dabrafenib + Trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: results of a randomized, phase 2, open-label multicenter trial. Thyroid 32(10), 1184–1192 (2022). https://doi.org/10.1089/thy.2022.0115

Article  CAS  PubMed  PubMed Central  Google Scholar 

- FDA grants accelerated approval to dabrafenib in combination with trametinib for unresectable or metastatic solid tumors with BRAF V600E mutation. Jun 22, 2022. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid.

F. Pitoia, F. Jerkovich, P. Trimboli, A. Smulever, New approaches for patients with advanced radioiodine-refractory thyroid cancer. World J. Clin. Oncol. 13(1), 9–27 (2022). https://doi.org/10.5306/wjco.v13.i1.9

Article  PubMed  PubMed Central  Google Scholar 

F. Jerkovich, M.G. García Falcone, F. Pitoia, The experience of an Endocrinology Division on the use of tyrosine multikinase inhibitor therapy in patients with radioiodine-resistant differentiated thyroid cancer. Endocrine 64(3), 632–638 (2019)

Article  CAS  PubMed  Google Scholar 

N. Treistman, G.M. Nobre, M.Y. Tramontin, G.M.W. da Silva, D. Herchenhorn, L.H. de Lima Araujo, F.A. de Andrade, R. Corbo, D. Bulzico, F. Vaisman, Prognostic factors in patients with advanced differentiated thyroid cancer treated with multikinase inhibitors—a single Brazilian center experience. Arch Endocrinol. Metab. 65(4), 411–420 (2021). https://doi.org/10.20945/2359-3997000000364

Article  PubMed  PubMed Central  Google Scholar 

M. Gallo, F. Michelon, A. Castiglione, F. Felicetti, A.A. Viansone, A. Nervo, C. Zichi, G. Ciccone, A. Piovesan, E. Arvat, Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center. Endocrine 49(3), 726–734 (2015). https://doi.org/10.1007/s12020-014-0481-x

Article  CAS  PubMed  Google Scholar 

M. Kim, T.H. Kim, D.Y. Shin, D.J. Lim, E.Y. Kim, W.B. Kim, J.H. Chung, Y.K. Shong, B.H. Kim, W.G. Kim; Korean Thyroid Cancer Study Group (KTCSG), Tertiary care experience of sorafenib in the treatment of progressive radioiodine-refractory differentiated thyroid carcinoma: a Korean multicenter study. Thyroid 28(3), 340–348 (2018). https://doi.org/10.1089/thy.2017.0356

Article  CAS  PubMed  PubMed Central  Google Scholar 

K. Sugino, M. Nagahama, W. Kitagawa, K. Ohkuwa, T. Uruno, K. Matsuzu, A. Suzuki, C. Masaki, J. Akaishi, K.Y. Hames, C. Tomoda, Y. Ogimi, K. Ito, Clinical factors related to the efficacy of tyrosine kinase inhibitor therapy in radioactive iodine refractory recurrent differentiated thyroid cancer patients. Endocr. J. 65(3), 299–306 (2018). https://doi.org/10.1507/endocrj

Article  CAS  PubMed  Google Scholar 

C. Masaki, K. Sugino, N. Saito, J. Akaishi, K.Y. Hames, C. Tomoda, A. Suzuki, K. Matsuzu, T. Uruno, K. Ohkuwa, W. Kitagawa, M. Nagahama, K. Ito, Efficacy and limitations of lenvatinib therapy for radioiodine-refractory differentiated thyroid cancer: real-world experiences. Thyroid 30(2), 214–221 (2020). https://doi.org/10.1089/thy.2019.0221

Article  CAS  PubMed  Google Scholar 

S. Hamidi, A. Boucher, B. Lemieux, G. Rondeau, R. Lebœuf, L.G. Ste-Marie, X.K. Le, H. Mircescu, Lenvatinib therapy for advanced thyroid cancer: real-life data on safety, efficacy, and some rare side effects. J. Endocr. Soc. 6(6), bvac048 (2022). https://doi.org/10.1210/jendso/bvac048

Article  CAS  PubMed  PubMed Central  Google Scholar 

A. Berdelou, I. Borget, Y. Godbert, T. Nguyen, M.E. Garcia, C.N. Chougnet, A. Ferru, C. Buffet, O. Chabre, O. Huillard, S. Leboulleux, M. Schlumberger, Lenvatinib for the treatment of radioiodine-refractory thyroid cancer in real-life practice. Thyroid 28(1), 72–78 (2018). https://doi.org/10.1089/thy.2017.0205

Article  CAS  PubMed  Google Scholar 

S. Jasim, N.M. Iniguez-Ariza, C.R. Hilger, A.V. Chintakuntlawar, M.M. Ryder, J.C. Morris 3rd, K.C. Bible, Optimizing lenvatinib therapy in patients with metastatic radioactive iodine-resistant differentiated thyroid cancers. Endocr. Pract. 23(10), 1254–1261 (2017). https://doi.org/10.4158/EP171822.OR

Article  PubMed  Google Scholar 

L.D. Locati, A. Piovesan, C. Durante, M. Bregni, M.G. Castagna, S. Zovato, M. Giusti, T. Ibrahim, E. Puxeddu, G. Fedele, G. Pellegriti, G. Rinaldi, D. Giuffrida, F. Verderame, F. Bertolini, C. Bergamini, A. Nervo, G. Grani, S. Rizzati, S. Morelli, I. Puliafito, R. Elisei, Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy. Eur. J. Cancer 118, 35–40 (2019). https://doi.org/10.1016/j.ejca.2019.05.031

Article  CAS  PubMed  Google Scholar 

E.K. Lee, S.M. Kim, B.H. Kim, M.J. Kim, D.J. Lim, M.H. Kim, D.Y. Shin, H.C. Kang, B.C. Ahn, S.W. Kim, H.Y. Ahn, Y.J. Park, Lesion-based evaluation predicts treatment response to lenvatinib for radioactive iodine-refractory differentiated thyroid cancer: a Korean multicenter retrospective study. Thyroid 29(12), 1811–1819 (2019). https://doi.org/10.1089/thy.2019.0022

Article  CAS  PubMed  Google Scholar 

M.D. Aydemirli, E. Kapiteijn, K.R.M. Ferrier, P.B. Ottevanger, T.P. Links, A.N.A. van der Horst-Schrivers, K.E. Broekman, R.H.H. Groenwold, J. Zwaveling, Effectiveness and toxicity of lenvatinib in refractory thyroid cancer: Dutch real-life data. Eur. J. Endocrinol. 182(2), 131–138 (2020). https://doi.org/10.1530/EJE-19-0763

Article  CAS  PubMed  Google Scholar 

F. Jerkovich, I. Califano, F. Bueno, J.M. Carrera, R. Giglio, E. Abelleira, F. Pitoia, Real-life use of lenvatinib in patients with differentiated thyroid cancer: experience from Argentina. Endocrine 69(1), 142–148 (2020). https://doi.org/10.1007/s12020-020-02290-9

Article  CAS  PubMed  Google Scholar 

Y. Ito, N. Onoda, T. Kudo, H. Masuoka, T. Higashiyama, M. Kihara, A. Miya, A. Miyauchi, Sorafenib and lenvatinib treatment for metastasis/recurrence of radioactive iodine-refractory differentiated thyroid carcinoma. In Vivo 35(2), 1057–1064 (2021). https://doi.org/10.21873/invivo.12350

Article  CAS